SUN W, ZHOU Y, LIN Y, FENG S, LONG H. [Advances of Neoadjuvant Targeted Therapy in ALK-positive Non-small Cell Lung Cancer].
ZHONGGUO FEI AI ZA ZHI = CHINESE JOURNAL OF LUNG CANCER 2024;
27:849-854. [PMID:
39800480 PMCID:
PMC11732383 DOI:
10.3779/j.issn.1009-3419.2024.106.30]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 10/15/2024] [Indexed: 01/16/2025]
Abstract
Lung cancer remains the most frequently diagnosed cancer and the leading cause of cancer-related death worldwide, with anaplastic lymphoma kinase (ALK) fusion mutations accounting for approximately 4%-9% of cases. In recent years, there are increasing clinical evidences suggesting that the combination of ALK inhibitors with surgical treatment holds significant potential for clinical application in resectable early and locally advanced non-small cell lung cancer (NSCLC) patients. This review aims to summarize the advances in neoadjuvant targeted therapy for ALK fusion positive NSCLC and discuss its advantages and challenges in clinical practice.
.
Collapse